|Polycystic Ovary Syndrome is Affected and Protected by DD and DI Genotypes of Angiotensin Converting Enzyme, Respectively: An Update of a Meta-Analysis|
|Fatemeh Yari1, Kamran Aeinfar2, Saber Abbaszadeh3, Khatereh Anbari4, Seyyed Amir Yasin Ahmadi3|
|1Depatment of Reproductive Health, Lorestan University of Medical Sciences, Khorramabad, Iran
2Rajaei Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
3Student Research Committee, Lorestan University of Medical Sciences, Khorramabad, Iran
4Department of Community Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
IJWHR 2017; 5: 164–170
Viewed : 767 times
Downloaded : 670 times.
Keywords : Angiotensin converting enzyme inhibitors, Meta-analysis, Polycystic ovary syndrome
|Full Text(PDF) | Related Articles|
Objectives: Angiotensin converting enzyme (ACE) is an important enzyme involved in the physiopathology of renal, cardiovascular and ovarian systems. One of these ACE related diseases is polycystic ovary syndrome (PCOS).
Materials and Methods: We intend to update the only meta-analysis written by Jia et al in 2013 on the association of ACE gene polymorphism and risk of PCOS. The reason of our attempt to update this meta-analysis was that they found no significant relation in their meta-analysis. For this aim, we searched in databases for relevant documents.
Results: We found 8 relevant papers, 6 of which had been covered by Jia et al meta-analysis. In order to perform this meta-analysis, we used comprehensive meta-analysis software. The analysis was done through P value and sample size of each study based on fixed-effect model. Analyses were performed in 5 different groups of alleles and genotypes. Among these 5 analyses, 4 of them were statistically significant. Hereby, we concluded that DD genotype of ACE is a risk factor for PCOS (P value = 0.013; odds ratio [OR] = 1.195), while DI is the protecting genotype (P = 0.009; OR = 0.819).
Conclusion: Hence, it is suggested to use a very low dose of captopril as an ACE inhibitor in the PCOS patients having DD genotype in future as a clinical trial, just as a scientific model. Further investigation on ovary ACE system is needed.
Cite By, Google Scholar